Pre-radiation enhances the cytotoxicity of docetaxel in head and neck squamous cell carcinoma cells

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1339-1343

  Furuse, Satori ^a   Adachi, Makoto ^a   Ijichi, Kei ^b   Ohta, Shinsuke ^c   Torigoe, Soichiro ^d   Nakazawa, Masatoshi ^a   Miura, Satoshi ^a   Mitsudo, Kenji ^a   Tohnai, Iwai ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

^d Yokohama Stroke and Brain Center   (Japan)

Author keywords

Cell cycle; Combination therapy; Docetaxel; Head and neck squamous cell carcinoma; Radiation

Indexed keywords

DOCETAXEL; PROTEIN P53;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IRRADIATION; MITOSIS INHIBITION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; RADIOTHERAPY, ADJUVANT; TAXOIDS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950807867     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000769     Document Type: Article

References (24)

1. Caponigro F, Longo F, Perri F and Ionna F: Docetaxel in the management of head and neck cancer. Anticancer Drugs 20: 639-645, 2009.
2. Colevas AD and Posner MR: Docetaxel in head and neck cancer: a review. Am J Clin Oncol 21: 482-486, 1998.
3. Zhao J, Kim JE, Reed E and Li QQ: Molecular mechanism of antitumor activity of taxanes in lung cancer. Int J Oncol 27: 247-256, 2005.
4. Hennequin C, Giocanti N and Favaudon V: S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71: 1194-1198, 1995.
5. Garcia P, Braguer D, Carles G, el Khyari S, Barra Y, de Ines C, Barasoain I and Briand C: Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother Pharmacol 34: 335-343, 1994.
6. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
7. Wakasa T, Inoue T, Kawai N, Murakami J, Kishi K and Fukui K: The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. Br J Radiol 75: 657-662, 2002.
8. Yip HT, Chopra R, Chakrabarti R, Veena MS, Ramamurthy B, Srivatsan ES and Wang MB: Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg 132: 317-326, 2006.
9. Kogashiwa Y, Yamauchi K, Nagafuji H, Matsuda T, Tsubosaka T, Tsutsumi T, Karaho T and Kohno N: Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer. Oncol Rep 22: 1163-1167, 2009.
10. Bernier J and Vrieling C: Docetaxel in the management of patients with head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 8: 1023-1032, 2008.
11. Hennequin C, Giocanti N and Favaudon V: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56: 1842-1850, 1996.
12. Gaglio T, Saredi A and Compton DA: NuMA is required for the organization of microtubules into aster-like mitotic arrays. J Cell Biol 131: 693-708, 1995.
13. Pradier O, Rave-Fränk M, Lehmann J, Lücke E, Boghun O, Hess CF and Schmidberger H: Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 91: 840-845, 2001.
14. Liu T, Zhang M, Zhang H, Sun C, Yang X, Deng Y and Ji W: Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 587: 78-84, 2008.
15. Choi EK, Ji IM, Lee SR, Kook YH, Griffin RJ, Lim BU, Kim JS, Lee DS, Song CW, Vorlaufer E and Peters JM: Regulation of the cyclin B degradation system by an inhibitor of mitotic proteolysis. Mol Biol Cell 9: 1817-1831, 1998.
16. Smits VA and Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 1519: 1-12, 2001.
17. Giacinti C and Giordano A: RB and cell cycle progression. Oncogene 25: 5220-5227, 2006.
18. Lu C and El-Deiry WS: Targeting p53 for enhanced radio-and chemosensitivity. Apoptosis 14: 597-606, 2009.
19. Roberts JR, Allison DC, Donehower RC and Rowinsky EK: Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 50: 710-716, 1990.
20. Noguchi S: Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 97: 813-820, 2006.
21. Cuddihy AR and Bristow RG: The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev 23: 237-257, 2004.
22. Sinclair WK and Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450-474, 1966.
23. Terasima T and Tolmach LJ: Variations in several response of Hela cells to X-irradiation during the division cycle. Biophys J 3: 11-33, 1963.
24. Geng CX, Zeng ZC, Wang JY, Xuan SY and Lin CM: Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol 11: 2990-2993, 2005.